Q2 2025 Management View CEO Robert I. Blum reported that "the FDA extended our PDUFA date for the NDA for aficamten for the treatment of patients with oHCM to December 26, 2025," adding that the ...

Discover key insights from SANUWAVE Health's Q2 2025 earnings call, highlighting record revenue growth, strong UltraMIST sales, and strategic growth plans.

Q2 2025 Management View President and CEO Nikhil Lalwani described Q2 2025 as a "record-setting quarter for our company with all-time overall company highs in net revenue, adjusted non-GAAP EBITDA and ...